Literature DB >> 10922279

Cost analysis of enteroviral polymerase chain reaction in infants with fever and cerebrospinal fluid pleocytosis.

L E Nigrovic1, V W Chiang.   

Abstract

BACKGROUND: Infants with fever and cerebrospinal fluid (CSF) pleocytosis are routinely admitted to the hospital for parenteral antibiotic therapy for potential bacterial meningitis pending results of CSF culture. Published estimates suggest that 90% of all episodes of meningitis are caused by enterovirus. Enteroviral polymerase chain reaction (ePCR) has a sensitivity of 92% to 100% and a specificity of 97% to 100% in CSF.
OBJECTIVE: To compare a management strategy using ePCR with current practice to determine potential savings by allowing earlier discharge.
METHODS: Decision analysis comparing 2 strategies for the care of a retrospective cohort of infants with fever and CSF pleocytosis: standard practice vs ePCR testing of all CSF samples. Model assumptions include the following: (1) standard practice patients continue parenteral antibiotic therapy until CSF cultures are negative at 48 hours, (2) patients with positive ePCR results would be discharged after 24 hours, (3) patients with positive ePCR results have a negative CSF culture, and (4) costs are calculated from actual patient charges with a cost-to-charge ratio of 0.65.
SUBJECTS: All infants aged 28 days to 12 months admitted to an urban teaching hospital with fever, CSF pleocytosis, and a negative CSF Gram stain from January 1996 through December 1997. OUTCOME MEASURE: Total cost of hospitalization.
RESULTS: A total of 126 infants were identified. One hundred twelve (89%) were discharged with a diagnosis of aseptic meningitis; 72% of these cases occurred during the peak enterovirus season (June to October). Three of 3 patients with positive CSF cultures had bacterial growth within 24 hours of admission. Mean length of stay for patients with aseptic meningitis was 2.3 days (SD, +/-1.4 days). Total cost of hospital care for all 126 infants was $381,145. In our patient population, total patient costs would be reduced by the ePCR strategy if enterovirus accounts for more than 5. 9% of all meningitis cases. Varying the sensitivity of the ePCR assay from 100% to 90% changes the "break-even" prevalence from 5.8% to 6.5%. Total cost savings of 10%, 20%, and 30% would occur at an enteroviral meningitis prevalence of 36.3%, 66.7%, and 97.1%, respectively.
CONCLUSIONS: Enteroviral PCR analysis of CSF for infants admitted to the hospital with meningitis can result in cost savings when the prevalence of enteroviral meningitis exceeds 5.9%. Limiting use of ePCR to the enterovirus season would increase cost savings. A prospective study is needed to validate these results. Arch Pediatr Adolesc Med. 2000;154:817-821

Entities:  

Mesh:

Year:  2000        PMID: 10922279     DOI: 10.1001/archpedi.154.8.817

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  23 in total

1.  Correlation of cerebrospinal fluid (CSF) cell counts and elevated CSF protein levels with enterovirus reverse transcription-PCR results in pediatric and adult patients.

Authors:  William S Mulford; Richard S Buller; Max Q Arens; Gregory A Storch
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  Molecular testing for infectious diseases should be done in the clinical microbiology laboratory.

Authors:  Nima Mosammaparast; Alexander J McAdam; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

3.  Quantitative PCR-enhanced immunoassay for measurement of enteroviral immunoglobulin M antibody and diagnosis of aseptic meningitis.

Authors:  Amal Elfaitouri; Nahla Mohamed; Jan Fohlman; Robert Aspholm; Gun Frisk; Göran Friman; Lars Magnius; Jonas Blomberg
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

4.  Real-time polymerase chain reaction detection of herpes simplex virus in cerebrospinal fluid and cost savings from earlier hospital discharge.

Authors:  Kenneth Rand; Herbert Houck; Robert Lawrence
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

Review 5.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

6.  Linking surveillance to action: incorporation of real-time regional data into a medical decision rule.

Authors:  Andrew M Fine; Lise E Nigrovic; Ben Y Reis; E Francis Cook; Kenneth D Mandl
Journal:  J Am Med Inform Assoc       Date:  2007-01-09       Impact factor: 4.497

7.  Impact of Enteroviral Polymerase Chain Reaction Testing on Length of Stay for Infants 60 Days Old or Younger.

Authors:  Paul L Aronson; Todd W Lyons; Andrea T Cruz; Stephen B Freedman; Pamela J Okada; Alesia H Fleming; Joseph L Arms; Amy D Thompson; Suzanne M Schmidt; Jeffrey Louie; Michael J Alfonzo; Michael C Monuteaux; Lise E Nigrovic
Journal:  J Pediatr       Date:  2017-07-10       Impact factor: 4.406

8.  Criteria for reducing unnecessary testing for herpes simplex virus, varicella-zoster virus, cytomegalovirus, and enterovirus in cerebrospinal fluid samples from adults.

Authors:  Craig B Wilen; Cynthia L Monaco; Joan Hoppe-Bauer; Ronald Jackups; Robert C Bucelli; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

9.  Cost of contralateral prophylactic mastectomy.

Authors:  Ashish A Deshmukh; Scott B Cantor; Melissa A Crosby; Wenli Dong; Yu Shen; Isabelle Bedrosian; Susan K Peterson; Patricia A Parker; Abenaa M Brewster
Journal:  Ann Surg Oncol       Date:  2014-05-09       Impact factor: 5.344

10.  Clinical presentation of patients with aseptic meningitis, factors influencing treatment and hospitalization, and consequences of enterovirus cerebrospinal fluid polymerase chain reaction testing.

Authors:  Glenn Patriquin; Jill Hatchette; Kevin Forward
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.